2024 State of Specialty Spend and Trend Report
With specialty drug spend on the rise and a robust pipeline of specialty drugs, specialty drug management remains a top concern for payers. The 2024…
GeneCQ, Gene Therapy Risk Mitigation
SOLUTIONS
Artemetrx GeneCQ
Artemetrx GeneCQ is a cutting-edge solution that empowers healthcare payers with data-driven insights to quantify exposure to high-cost gene therapies more accurately. This technology utilizes sophisticated algorithms to analyze clinical, demographic, diagnosis, and medication use data to identify the level of risk for individual members within specific populations of approved and late-stage pipeline gene therapies.
gene, cell, and RNA therapies in development
potential cost of a single gene therapy
estimated growth in CGT spend over the next 5 years
Risk-Adjusted Cost Analysis for Gene Therapy
Artemetrx GeneCQ provides powerful, unique algorithms for one-time, curative, non-oncology gene therapies currently available on the market, as well as those expected to be available in the next year. We have strengthened this analysis by incorporating actuarial modeling techniques to provide the most comprehensive picture of potential costs and the associated timing.
Member-Level Identification
Built on the Artemetrx pharmacy and medical claims integrated dataset, GeneCQ analyzes clinical history, demographics, diagnoses, and medication use. It calibrates a member-level risk score based on data and market insights related to ideal patient characteristics and uptake.
Census-Based Analysis
GeneCQ algorithms leverage our proprietary actuarial models based on clinical and demographic attributes to quantify additional cost exposure not apparent within retrospective claims. This analysis is designed to account for instances of new members added to the plan as well as newly diagnosis patients of rare diseases.